Markus Warmuth - 01 Mar 2022 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Reporting relationship: President & CEO, Director
Issuer ticker: GLUE
Reported as of: 01 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Mar 2022, 17:26:59 UTC
Prior SEC filing: 23 Jun 2021
Next SEC filing: 04 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Ajim Tamboli, Attorney-in-Fact

Key filing fact

Markus Warmuth filed Form 4 for Monte Rosa Therapeutics, Inc. (GLUE) on 02 Mar 2022.

Key facts

This page summarizes Markus Warmuth's Form 4 filing for Monte Rosa Therapeutics, Inc. (GLUE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Mar 2022, 17:26.

Change

Previous filing in this sequence was filed on 23 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GLUE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +315,600
Change %
Price: $0.000000
Shares after: 315,600
Date: 01 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 315,600
Exercise price: $13.41
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter.